Important Points (Bullets):
- Approval Authority:
- Approved by Swiss authorities in a global first.
Target Group:
- Specifically designed for infants weighing 2–5 kg (newborns to under 6 months).
Drug Composition:
- Artemether and Lumefantrine – a fixed-dose combination effective against Plasmodium parasites.
Developed By:
- Novartis in collaboration with:
- Medicines for Malaria Venture (MMV)
- Governments of UK, Switzerland, Netherlands
- World Bank and Rockefeller Foundation
Need for the Drug:
- Infants were previously treated with formulations meant for older children, increasing risk of overdose and inefficacy.
Formulation Benefits:
- Dissolves easily in breast milk.
- Has a sweet cherry flavor for easier consumption.
- Designed to be safe and age-appropriate.
Clinical Trials:
- Conducted across 8 African countries, including:
- Nigeria, Kenya, Uganda, Malawi, Mozambique, Tanzania, Burkina Faso, Ivory Coast.
Quick Facts About Malaria (Relevance):
- Cause:
- Caused by Plasmodium parasites, spread through female Anopheles mosquitoes.
Dangerous Species:
- Plasmodium falciparum (most lethal) and Plasmodium vivax.
Transmission:
- Not contagious between people, but can spread through infected blood or contaminated needles.
Symptoms (10–15 days post-infection):
- Fever, chills, headache, fatigue.
- Severe: Seizures, breathing difficulty, jaundice, death if untreated.
Immunity:
- Partial immunity may develop in endemic regions, complicating diagnosis.